The invention disclose a compound of formula (I), wherein, R.sub.1 is selected from —H or C1-C6 hydrocarbon group, —NH.sub.2, —OH, —O(CH.sub.2).sub.nCH.sub.3 (n=0, 1 or 2), —N(CH.sub.3).sub.2, or —CH.sub.2N(CH.sub.3).sub.2, R.sub.2 is selected from an amino acid

##STR00001##

or an hydroxy acid

##STR00002##

or —OH (R.sub.1, R.sub.2 are not —CH.sub.3 and —OH at the same time), wherein X, Y are

##STR00003##

—H, —CH.sub.3, —CH.sub.2OH, —CH(OH)CH.sub.3, —CH.sub.2SH, —CH(CH.sub.3).sub.2, —CH.sub.2CH(CH.sub.3).sub.2, —CH(CH.sub.3)CH.sub.2CH.sub.3, —CH.sub.2CH.sub.2SCH.sub.3, —CH.sub.2COOH, —CH.sub.2CONH.sub.2, —CH.sub.2CH.sub.2COOH, —CH.sub.2CH.sub.2CH.sub.2CH.sub.2NH.sub.2, or —CH.sub.2CH.sub.2CONH.sub.2, R.sub.3-R.sub.5 are H or C1-C6 hydrocarbon group. The compound has a low toxicity, can significantly inhibit the migration and invasion of tumor cells in vitro, and can inhibit tumor metastasis in vivo in mice at low concentration, while showing notable sensitizing effect on cytotoxic anti-tumor drugs such as Paclitaxel etc.

##STR00004##

The invention disclose a compound of formula (I), wherein, R.sub.1 is selected from —H or C1-C6 hydrocarbon group, —NH.sub.2, —OH, —O(CH.sub.2).sub.nCH.sub.3 (n=0, 1 or 2), —N(CH.sub.3).sub.2, or —CH.sub.2N(CH.sub.3).sub.2, R.sub.2 is selected from an amino acid

##STR00001##

or an hydroxy acid

##STR00002##

or —OH (R.sub.1, R.sub.2 are not —CH.sub.3 and —OH at the same time), wherein X, Y are

##STR00003##

—H, —CH.sub.3, —CH.sub.2OH, —CH(OH)CH.sub.3, —CH.sub.2SH, —CH(CH.sub.3).sub.2, —CH.sub.2CH(CH.sub.3).sub.2, —CH(CH.sub.3)CH.sub.2CH.sub.3, —CH.sub.2CH.sub.2SCH.sub.3, —CH.sub.2COOH, —CH.sub.2CONH.sub.2, —CH.sub.2CH.sub.2COOH, —CH.sub.2CH.sub.2CH.sub.2CH.sub.2NH.sub.2, or —CH.sub.2CH.sub.2CONH.sub.2, R.sub.3-R.sub.5 are H or C1-C6 hydrocarbon group. The compound has a low toxicity, can significantly inhibit the migration and invasion of tumor cells in vitro, and can inhibit tumor metastasis in vivo in mice at low concentration, while showing notable sensitizing effect on cytotoxic anti-tumor drugs such as Paclitaxel etc.

##STR00004##

Compounds of the formula (I), in which the substituents are as defined in claim 1, are suitable for use as nematicides. ##STR00001##

Compounds of the formula (I), in which the substituents are as defined in claim 1, are suitable for use as nematicides. ##STR00001##

Provided herein are deuterated compounds and compositions useful in increasing PPARδ activity. The compounds and compositions provided herein are useful for the treatment of PPARδ related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).

The present disclosure provides a compound of Formula (I):

##STR00001##

or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (Formula (I)). Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder. ##STR00001##

A compound including a structure of Formula (I) and a preparation method thereof,

##STR00001##

wherein R.sub.1 is —OH, —CH.sub.2OH, or —OCOCH.sub.3; R.sub.2, R.sub.3, and R.sub.4 are independently —H, —CH.sub.3 or —F, and at least one of R.sub.2, R.sub.3, and R.sub.4 is —F. A method for treating a subject suffering from a viral disease includes administering an effective amount of said compound or a solvate thereof to the subject.

A compound including a structure of Formula (I) and a preparation method thereof,

##STR00001##

wherein R.sub.1 is —OH, —CH.sub.2OH, or —OCOCH.sub.3; R.sub.2, R.sub.3, and R.sub.4 are independently —H, —CH.sub.3 or —F, and at least one of R.sub.2, R.sub.3, and R.sub.4 is —F. A method for treating a subject suffering from a viral disease includes administering an effective amount of said compound or a solvate thereof to the subject.

The invention relates to KDM4B inhibitors, compositions comprising an effective amount of KDM4B inhibitors and methods for treating inflammatory diseases and disorders.